Publications

Detailed Information

Silver nanoparticles promote procoagulant activity of red blood cells: a potential risk of thrombosis in susceptible population

DC Field Value Language
dc.contributor.authorBian, Yiying-
dc.contributor.authorKim, Keunyoung-
dc.contributor.authorNgo, Thien-
dc.contributor.authorKim, Inho-
dc.contributor.authorBae, Ok-Nam-
dc.contributor.authorLim, Kyung-Min-
dc.contributor.authorChung, Jin-Ho-
dc.date.accessioned2019-03-19T05:32:29Z-
dc.date.available2019-03-19T14:33:16Z-
dc.date.issued2019-02-14-
dc.identifier.citationParticle and Fibre Toxicology. 2019 Feb 14;16(1):9ko_KR
dc.identifier.issn1743-8977-
dc.identifier.urihttps://hdl.handle.net/10371/147182-
dc.description.abstractBackground
Silver nanoparticles (AgNP) are widely used in medical practices owing to their distinct antibacterial, antiviral and anticancer activities. However, with increasing use of AgNP, concerns over its potential toxicity are also escalating. Here, we demonstrated the potential thrombotic effect of AgNP which was mediated by the procoagulant activity of red blood cells (RBCs).

Results
In freshly isolated human RBCs, AgNP, but not silver microparticles (AgMP), elicited morphological changes, phosphatidylserine (PS) exposure and microvesicles (MV) generation, the key indicators of procoagulant activity in RBCs at concentration ranges (≤ 100 μg/mL) that were free of significant hemolysis. In line with this, AgNP potentiated thrombin generation and adherence of RBCs to endothelial cells, while AgMP did not. Oxidative stress, intracellular calcium increase and ATP depletion were found to underlie the procoagulant effects of AgNP, which led to altered activity of membrane aminophospholipid translocases. These in vitro findings were well reproduced in rat in vivo, where intravenously exposure to AgNP promoted venous thrombosis significantly. Of note, RBCs isolated from cancer patients, who inherently convey the risk of thrombogenesis, were more sensitive to the procoagulant effects of AgNP. In addition, AgNP significantly potentiated the procoagulant effects of a chemotherapeutic drug, paclitaxel.

Conclusion
Collectively, these results suggest that AgNP may have prothrombotic risks by promoting procoagulant activity of RBCs and caution shall be taken for its use in the population sensitive to thrombosis like cancer patients.
ko_KR
dc.description.sponsorshipThis research was supported by a grant (#HI16C2044) of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea.ko_KR
dc.language.isoenko_KR
dc.publisherBioMed Centralko_KR
dc.subjectSilver nanoparticles (AgNP)ko_KR
dc.subjectToxicityko_KR
dc.subjectThrombosisko_KR
dc.subjectRed blood cells (RBCs)ko_KR
dc.subjectCancerko_KR
dc.titleSilver nanoparticles promote procoagulant activity of red blood cells: a potential risk of thrombosis in susceptible populationko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김근영-
dc.contributor.AlternativeAuthor김인호-
dc.contributor.AlternativeAuthor배옥남-
dc.contributor.AlternativeAuthor임경민-
dc.contributor.AlternativeAuthor정진호-
dc.identifier.doi10.1186/s12989-019-0292-6-
dc.language.rfc3066en-
dc.rights.holderThe Author(s).-
dc.date.updated2019-02-17T04:18:53Z-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share